Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease.

1982 ◽  
Vol 28 (1) ◽  
pp. 183-186 ◽  
Author(s):  
J Griffiths ◽  
D F Rippe ◽  
P R Panfili
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Immunosorbent Assay ◽  
Digital Rectal Examination ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Prostatic Adenocarcinoma ◽  
Enzyme Linked Immunosorbent Assay ◽  
Specific Enzyme ◽  
Prostatic Disease

Abstract We compared results by an enzyme-linked immunosorbent assay (ELISA) with those by a standard radioimmunoassay (RIA) for detection and quantitation of prostate-specific acid phosphatase (EC 3.1.3.2) in serum. Control subjects, patients with benign prostatic hyperplasia, and patients in all four clinical stages of prostatic adenocarcinoma were tested. The upper limit of normal (95% of the population) by the ELISA was 2.0 micrograms/L, and by the RIA was 2.2 micrograms/L. In prostatic adenocarcinoma stage I (not detectable by digital rectal examination), ELISA was slightly more sensitive than RIA, but sensitivity was still relatively low (20%). As tumor mass increased (stages II through IV), the frequency of increased concentrations of prostatic acid phosphatase in serum also increased. We confirmed this increase in circulating enzyme in some cases of benign prostatic hyperplasia and suggest that this finding is related to either acinar cytolysis or an increase in acini size and number. Although prostate-specific acid phosphatase is not a cancer-specific enzyme, we conclude that its measurement may be of considerable value in monitoring prostatic disease.

Rapid radioimmunoassay for prostate-specific acid phosphatase in human serum.

1980 ◽  
Vol 26 (11) ◽  
pp. 1544-1547 ◽  
Author(s):  
P Vihko ◽  
A Kostama ◽  
O Jänne ◽  
E Sajanti ◽  
R Vihko
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Reference Group ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Serum Concentrations ◽  
Healthy Men ◽  
Monospecific Antisera ◽  
Group Serum

Abstract We describe a rapid radioimmunoassay for human prostatic acid phosphatase (EC 3.1.3.2) in serum, with use of monospecific antisera raised in rabbits against the primary highly purified acid phosphatase (pl 4.9) from human prostates, and with a second antibody-polyethylene glycol porecipitation. This radioimmunoassay is sensitive and can be performed within 5 h. Concentrations of the immunoreactive acid phosphatase in sera of healthy men (n = 394) ranged from 0.3 to 3.6 microgram/L (mean 1.94, SD 0.66 microgram/L). Concentrations of the enzyme in sera of men with benign prostatic hyperplasia (n = 56) or with carcinoma of nonprostatic origin (n = 24) were identical with those of the reference group. Serum concentrations of immunoreactive prostatic acid phosphatase of patients with occult, non-metastatic, and metastatic prostatic carcinoma varied from 1.7 to 9.3 (n = 9), 4.2 to 59.4 (n = 12), and 20 to 198 (n = 10) microgram/L, respectively. The amount of immunoassayable prostatic acid phosphatase was unchanged for at least five days in serum stored at 4 degrees C.

Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1-42 days after transurethral resection of the prostate and orchidectomy

1991 ◽  
Vol 37 (6) ◽  
pp. 859-863 ◽  
Author(s):  
Alun Price ◽  
Stephen E A Attwood ◽  
jhon B F Grant ◽  
Trevour A Gray ◽  
Kenneth T H Moore
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Antigen Concentration ◽  
The Third ◽  
Diagnostic Usefulness

Abstract Preoperative intra-individual variation for determinations of prostate-specific antigen and prostatic acid phosphatase concentrations, 15-30% in 92 patients with benign prostatic hyperplasia, limits the diagnostic usefulness of both tumor markers. In benign prostatic hyperplasia (214 patients), concentrations of these tumor markers increased in the initial postoperative period. Prostatic acid phosphatase concentration then decreased by the third postoperative day. Prostate-specific antigen concentration remained above normal in the first postoperative week but had decreased by 42 days. In prostatic carcinoma (46 patients), the concentrations of these tumor markers did not increase postoperatively. During the first week, the concentrations of prostatic acid phosphatase began to fall, but prostate-specific antigen showed a decrease only at 42 days. After orchidectomy (11 patients), the concentrations of both markers had decreased by five days. Concentrations of prostate-specific antigen but not of prostatic acid phosphatase were significantly increased in patients with metastases at 42 days postoperatively. When the concentration of tumor marker did decrease, the magnitude of change was greater for prostatic acid phosphatase than for prostate-specific antigen. These changes were accentuated after an orchidectomy.

Monitoring of Prostatic Cancer by an Enzyme-Linked Immunosorbent Assay of Serum Prostatic Acid Phosphatase

1983 ◽  
Vol 9 (1) ◽  
pp. 17-23 ◽  
Author(s):  
E.H. Cooper ◽  
N.B. Pidcock ◽  
D. Daponte ◽  
R.W. Glashan ◽  
E. Rowe ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Immunosorbent Assay ◽  
Prostatic Cancer ◽  
Prostatic Acid Phosphatase ◽  
Enzyme Linked Immunosorbent Assay

Transient increase in serum creatine kinase isoenzyme BB activity after prostatectomy in a patient with massive benign prostatic hyperplasia.

1980 ◽  
Vol 26 (3) ◽  
pp. 511-512
Author(s):  
Z D Goodman ◽  
S R Hamilton
Keyword(s):  
Creatine Kinase ◽  
Benign Prostatic Hyperplasia ◽  
Myocardial Injury ◽  
Prostate Gland ◽  
Serum Creatine Kinase ◽  
Prostatic Hyperplasia ◽  
Prostatic Adenocarcinoma ◽  
Agarose Gel Electrophoresis ◽  
Creatine Kinase Isoenzyme ◽  
Prostatic Disease

Abstract The activity of creatine kinase isoenzyme BB (CK-BB) in serum is rarely abnormally high (i.e., detectable). An increase in immunoreactive CK-BB or CK-BB activity in patients with prostatic disease has been proposed as an indication of prostatic adenocarcinoma. Here we report the case of an elderly man with massive benign prostatic hyperplasia but no clinical or pathological evidence of prostatic adenocarcinoma, whose serum CK-BB activity was found by agarose gel electrophoresis to be 1 U/L (normal: 0%), 10% of his total CK activity. Serum CK-BB activity was further increased to 16 U/L (20% of total CK activity) 1 h after prostatectomy, but became undetectable by the second day after the operation. The findings suggest that: (a) the source of the serum CK-BB activity was the enlarged prostate gland; (b) abnormally high CK-BB activity in serum of men with prostatic disease does not necessarily indicate the presence of prostatic adenocarcinoma; and (c) myocardial injury could be erroneously diagnosed postoperatively in prostatectomy patients if CK isoenzyme methods are used that do not consistently separate "heart-specific" CK-MB from CK-BB.

Transient increase in serum creatine kinase isoenzyme BB activity after prostatectomy in a patient with massive benign prostatic hyperplasia.

1980 ◽  
Vol 26 (3) ◽  
pp. 511-512
Author(s):  
Z D Goodman ◽  
S R Hamilton
Keyword(s):  
Creatine Kinase ◽  
Benign Prostatic Hyperplasia ◽  
Myocardial Injury ◽  
Prostate Gland ◽  
Serum Creatine Kinase ◽  
Prostatic Hyperplasia ◽  
Prostatic Adenocarcinoma ◽  
Agarose Gel Electrophoresis ◽  
Creatine Kinase Isoenzyme ◽  
Prostatic Disease

Abstract The activity of creatine kinase isoenzyme BB (CK-BB) in serum is rarely abnormally high (i.e., detectable). An increase in immunoreactive CK-BB or CK-BB activity in patients with prostatic disease has been proposed as an indication of prostatic adenocarcinoma. Here we report the case of an elderly man with massive benign prostatic hyperplasia but no clinical or pathological evidence of prostatic adenocarcinoma, whose serum CK-BB activity was found by agarose gel electrophoresis to be 1 U/L (normal: 0%), 10% of his total CK activity. Serum CK-BB activity was further increased to 16 U/L (20% of total CK activity) 1 h after prostatectomy, but became undetectable by the second day after the operation. The findings suggest that: (a) the source of the serum CK-BB activity was the enlarged prostate gland; (b) abnormally high CK-BB activity in serum of men with prostatic disease does not necessarily indicate the presence of prostatic adenocarcinoma; and (c) myocardial injury could be erroneously diagnosed postoperatively in prostatectomy patients if CK isoenzyme methods are used that do not consistently separate "heart-specific" CK-MB from CK-BB.

Sign in / Sign up

Export Citation Format

Share Document